Cardiovascular collaboration

Tuesday, 10 May, 2005

Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.

The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.

Related News

CytoCell University offers training on FISH

CytoCell University aims to partner with scientists to provide innovative and expert training on...

BioAgilytix to purchase Australia's 360biolabs

BioAgilytix Labs describes 360biolabs as the most comprehensive contract research organisation in...

$39.8m in govt funding to support women in STEM

The Office for Women is providing $39.8 million over three years to 60 organisations as part of...


  • All content Copyright © 2021 Westwick-Farrow Pty Ltd